Valiant Laboratories Limited (NSE: VALIANTLAB | BSE: 543998)

By Raveendran R | Updated on:

Source: Valiant Laboratories Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹237.47 Cr (▲ 78.0%)
Prev Year: ₹133.38 Cr
Gross Profit
₹40.31 Cr (▲ 140.2%)
Prev Year: ₹16.78 Cr
Operating Profit
₹0.35 Cr (▲ N/M)
Prev Year: -₹6.76 Cr
Net Profit
-₹3.27 Cr (▼ 48.6%)
Prev Year: -₹2.20 Cr
Ratios & Margins (% / x)
Gross Margin
16.97 % (▲ 439 bps)
Prev Year: 12.58 %
Operating Margin
0.15 % (▲ 522 bps)
Prev Year: -5.07 %
PAT Margin
-1.38 % (▲ 27 bps)
Prev Year: -1.65 %
ROCE
0.10 % (▲ 208 bps)
Prev Year: -1.98 %
ROE
-1.05 % (▼ 11 bps)
Prev Year: -0.94 %
ROA
-0.70 % (▼ 16 bps)
Prev Year: -0.55 %
Asset Turnover
0.51x (▲ 0.18 pts)
Prev Year: 0.33x
Balance Sheet (₹ Cr)
Total Assets
₹463.98 Cr (▲ 15.7%)
Prev Year: ₹400.86 Cr
Current Assets
₹228.32 Cr (▲ 18.5%)
Prev Year: ₹192.62 Cr
Total Liabilities
₹153.10 Cr (▼ 8.1%)
Prev Year: ₹166.55 Cr
Current Liabilities
₹119.45 Cr (▲ 100.4%)
Prev Year: ₹59.62 Cr
Total Debt
₹44.95 Cr (▼ 62.9%)
Prev Year: ₹121.21 Cr
Total Equity
₹310.89 Cr (▲ 32.7%)
Prev Year: ₹234.31 Cr
Working Capital
₹108.87 Cr (▼ 18.1%)
Prev Year: ₹133.00 Cr
Ratios & Margins (% / x)
Current Ratio
1.91x (▼ 1.32 pts)
Prev Year: 3.23x
Debt to Equity
0.14x (▼ 0.37 pts)
Prev Year: 0.52x
Debt to Assets
0.10x (▼ 0.21 pts)
Prev Year: 0.30x
Equity Multiplier
1.49x (▼ 0.22 pts)
Prev Year: 1.71x
Cash Flow (₹ Cr)
Operating Cash Flow
-₹10.43 Cr (▼ N/M)
Prev Year: ₹1.31 Cr
CapEx
₹34.20 Cr (▼ 70.0%)
Prev Year: ₹113.85 Cr
Free Cash Flow
-₹44.63 Cr (▲ 60.3%)
Prev Year: -₹112.54 Cr
Ratios & Margins (% / x)
FCF Margin
-18.79 % (▲ 6558 bps)
Prev Year: -84.38 %
Cash ROCE
-3.03 % (▼ 341 bps)
Prev Year: 0.38 %
Cash ROE
-3.35 % (▼ 391 bps)
Prev Year: 0.56 %
CF to Debt
-0.23x (▼ 0.24 pts)
Prev Year: 0.01x

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Valiant Laboratories Limited
Corporate Identity Number (CIN) L24299MH2021PLC365904
ISIN INE0OK501015
NSE Symbol & BSE Scrip Code NSE Symbol: VALIANTLAB | BSE Code: 543998
Date of Incorporation / Founding Year Originally formed as a partnership firm in 1980 as M/s. Bharat Chemicals; Converted into a public limited company on August 16, 2021
Founders / Key Founding Figures Mr. Chandrakant V. Gogri (Founder of Aarti Group of Industries)
Registered Office & Corporate Headquarters Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080, Maharashtra. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai – 400083, Maharashtra.
Telephone & Investor Relations Contact T: 022-49717221 / 49712001 / 49717220 | E: investor@valiantlabs.in
Chairman / Managing Director & CEO Mr. Mulesh Savla (Chairman & Non-Executive Independent Director) | Mr. Santosh Vora (Managing Director)
Chief Financial Officer (CFO) & Company Secretary (CS) Mr. Paresh Shah (Whole-Time Director & Chief Financial Officer) | Mr. Akshay Gangurde (Company Secretary & Compliance Officer)
Promoter & Holding Group Part of the Aarti Group of Industries (Holding Entity: Dhanvallabh Ventures LLP)
Industry / Sector Classification Pharmaceuticals / Active Pharmaceutical Ingredients (APIs) & Specialty Chemicals
Total Employees / Permanent & Contractual Workforce 84 permanent employees on rolls as on March 31, 2026
Manufacturing Plants / Branches / Offices Count Manufacturing facility at Tarapur Industrial Estate, Palghar, Maharashtra; Wholly-owned subsidiary greenfield facility at Saykha GIDC, Bharuch, Gujarat
Countries / States Served Domestic Indian markets and international export destinations
Statutory Auditors M/s. Raman S. Shah & Co., Chartered Accountants
Registrar and Share Transfer Agent (RTA) MUFG Intime India Pvt. Ltd. (C-101, 247 Park, L.B.S. Road, Vikhroli (West), Mumbai – 400083)

🏢 The Corporate Identity: Valiant Laboratories Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Valiant Laboratories Limited is a pharmaceutical company and one of India’s leading manufacturers of high-quality Active Pharmaceutical Ingredients (APIs), maintaining a strong specialized focus within the Paracetamol API segment. Backed by over 45 years of manufacturing excellence originating from the Aarti Group legacy, the Company operates an integrated production ecosystem engineered to deliver superior quality products punctually and at competitive prices. Through structured backward integration, technological process innovation, and rigorous quality systems, the Company bridges critical raw material sourcing with scalable pharmaceutical production to serve domestic and international healthcare markets.

The Founders, Promoters & Their Legacy

The enterprise traces its foundational roots back to 1980 with Bharat Chemicals, established by Mr. Chandrakant V. Gogri, the founder of Aarti Industries Limited. Mr. Gogri holds a degree in Chemical Engineering from the Institute of Chemical Technology (ICT) and brought unparalleled expertise in chemical industry projects, operations, process development, and marketing. Operating as an integral part of the Aarti Group, Valiant Laboratories benefits from this enduring legacy, leveraging decades of technical mastery in complex chemistries—such as Para Nitro Phenol production—to drive its pharmaceutical expansion and strategic positioning.

The Journey: Corporate History & Key Milestones

The evolution of the manufacturing and corporate footprint spans several defining milestones across four decades:

  • 1980: Established as a partnership firm under the name M/s. Bharat Chemicals, marking the beginning of the manufacturing journey.
  • 1982: Commenced the manufacturing of Paracetamol.
  • 2004–2005: Expanded the Tarapur presence with the acquisition of plots L-28, L-29, and L-13 (part), taking the total manufacturing footprint to approximately 3,000 square meters.
  • 2021: Converted from a partnership firm into a public limited company under the name Valiant Laboratories Limited on August 16, 2021; annual revenue from operations crossed ₹1.00 Crores.
  • 2022: Annual revenue from operations crossed ₹0.20 Crores; formed the wholly-owned subsidiary Valiant Advanced Sciences Private Limited (VASPL) to diversify business activities.
  • 2023: Successfully completed its Initial Public Offering (IPO) and listed equity shares on BSE and NSE on October 6, 2023.
  • 2025: Enhanced Tarapur manufacturing capacity from 9,000 MT to 10,800 MT per annum. Commercialised VASPL’s specialty chemicals greenfield facility at Saykha, Gujarat in November 2025, marking its transition into commercial production of ketene and diketene derivatives. Completed a Rights Issue raising ₹0.81 Crores in August 2025 to fully repay term borrowings.

The Corporate Umbrella & Group Structure

Valiant Laboratories Limited operates as a public listed entity within the Aarti Group. The Company holds 100% equity ownership in its material wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), which houses the newly commissioned greenfield specialty chemicals manufacturing plant at Saykha, Gujarat. This group structure establishes complete backward integration for the parent company’s core Paracetamol operations, securing key starting materials locally within the corporate network.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

The Company is engaged in the manufacture and sale of Active Pharmaceutical Ingredients, principally Paracetamol API. In accordance with Ind AS 108 – Operating Segments, the Chief Operating Decision Maker reviews the business as a single operating segment (Pharmaceuticals). Consequently, separate segment reporting is not applicable.

Consolidated Revenue Particulars FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Sale of Manufactured Products 229.29 129.72 +76.76%
Sale of Traded Products 5.17 0.66 +683.33%
Other Operating Revenue 3.00 3.00 0.00%
Total Revenue from Operations 237.47 133.38 +78.04%

The Product & Service Catalog (with Operational KPIs & Order Book)

The Company specializes in the production of Paracetamol Active Pharmaceutical Ingredients across diverse pharmacopeial grades and particle specifications tailored to customer finishing needs:

  • Pharmacopeial Standards: Paracetamol IP, BP, EP, and USP grades.
  • Physical Grades: Crystal, Powder, Fine Powder, and Pulverised grades.
  • Packaging Formats: Packed in drums, bags, or customized customer requirements.
  • Manufacturing Capacity: Tarapur facility capacity enhanced from 9,000 MT to 10,800 MT per annum during FY 2025-26.
  • Subsidiary Production: VASPL commenced commercial production of Acetic Anhydride and specialty chemicals at Saykha, Gujarat in November 2025.

The Names You Know: Key Brands & Flagship Portfolio

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Paracetamol API (IP / BP / EP / USP) Active Pharmaceutical Ingredient (Analgesic & Antipyretic) Global and domestic pharmaceutical finished dosage manufacturers for tablets, capsules, and oral liquid formulations.
Acetic Anhydride & Specialty Chemicals Specialty Chemicals (VASPL Subsidiary) End-use applications in agrochemical, pharmaceutical, dye, pigment, fragrance, food, and polymer industries.

Mapping the Domestic & Global Reach (India vs. Exports)

The Company maintains a robust domestic distribution footprint across India while expanding its export reach into semi-regulated and international markets supported by ISO 9001:2015 and GMP certifications.

Geographical Segment Revenue FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Within India (Domestic) 233.37 132.74 +75.81%
Outside India (Exports) 4.10 0.64 +540.62%
Total Revenue from Operations 237.47 133.38 +78.04%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

Operational infrastructure is anchored by key strategic locations designed for optimal logistics efficiency:

  • Tarapur Manufacturing Facility: Located at Plots L-13, L-28, L-28(Pt), L-29 & L-30, M.I.D.C., Tarapur, Boisar, District Palghar – 401506, Maharashtra. Strategically situated approximately 150 km from JNPT (Nhava Sheva) Port and 110 km from the Mumbai corporate office.
  • Saykha Greenfield Facility (VASPL): Located at Saykha GIDC, Bharuch, Gujarat, housing specialty chemical manufacturing operations with ISO 9001, ISO 14001, and ISO 45001 management systems certifications.
  • Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai – 400083, Maharashtra.
  • Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080, Maharashtra.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores / Lakhs Standalone & Consolidated Summary)

Standalone Financial Parameter FY 2025-26 FY 2024-25 FY 2023-24 FY 2022-23 Latest YoY (%)
Revenue from Operations (₹ in Crores) 237.47 133.38 182.05 333.91 +78.04%
EBITDA (₹ in Crores) 10.07 0.75 1.27 39.95 +1242.67%
EBITDA Margin (%) 4.64% 0.56% 0.70% 11.97% –
Profit Before Tax / PBT (₹ in Crores) 7.55 (1.45) (0.75) 38.14 N/M
Profit After Tax / PAT (₹ in Crores) 5.55 (2.15) 0.34 29.00 N/M

Earnings, Expenses, & Take-Home Profits (Consolidated Statement of Profit & Loss)

Consolidated Statement of Profit & Loss FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 237.47 133.38 +78.04%
Other Income 2.32 5.43 -57.27%
Total Income 239.79 138.82 +72.73%
Cost of Materials Consumed 190.80 112.18 +70.08%
Purchase of Stock-in-Trade 9.04 0.56 +1514.29%
Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress (2.68) 3.86 N/M
Employee Benefits Expense 7.00 4.39 +59.45%
Finance Costs 1.90 0.18 +955.56%
Depreciation, Amortization and Impairment Expenses 6.04 2.09 +189.00%
Other Expenses 26.92 17.07 +57.70%
Total Expenses 239.02 140.33 +70.33%
Profit / (Loss) Before Tax 0.77 (1.51) N/M
Tax Expense (Current & Deferred) 4.04 0.69 +485.51%
Profit / (Loss) for the Year (3.27) (2.20) +48.64%
Other Comprehensive Income / (Loss) (Net of Tax) 0.00 (0.02) -100.00%
Total Comprehensive Income / (Loss) for the Year (3.26) (2.23) +46.19%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

Consolidated Balance Sheet Particulars As at March 31, 2026 (₹ in Crores) As at March 31, 2025 (₹ in Crores) Latest YoY (%)
ASSETS
Property, Plant and Equipment 225.79 47.88 +371.57%
Right-of-Use Assets 1.23 0.45 +173.33%
Capital Work-in-Progress (CWIP) 6.08 155.78 -96.10%
Other Intangible Assets 0.11 0.11 0.00%
Other Financial Assets (Non-Current) 2.41 3.57 -32.49%
Other Non-Current Assets 0.04 0.45 -91.11%
Total Non-Current Assets 235.65 208.24 +13.16%
Inventories 45.43 3.99 +1038.60%
Investments (Current) 26.09 – –
Trade Receivables 93.56 72.12 +29.73%
Cash and Cash Equivalents 3.53 4.92 -28.25%
Bank Balances Other than Cash & Cash Equivalents 3.53 71.07 -95.03%
Loans (Current) 0.04 0.06 -33.33%
Other Current Assets 54.46 38.26 +42.34%
Current Tax Assets (Net) 1.68 2.19 -23.29%
Total Current Assets 228.32 192.62 +18.53%
TOTAL ASSETS 463.98 400.86 +15.75%
EQUITY AND LIABILITIES
Equity Share Capital 54.31 43.45 +24.99%
Other Equity 256.57 190.86 +34.43%
Total Equity (Net Worth) 310.89 234.31 +32.68%
Borrowings (Non-Current) 28.09 104.35 -73.08%
Lease Liabilities (Non-Current) 0.80 0.25 +220.00%
Other Non-Financial Liabilities 0.96 0.96 0.00%
Provisions (Non-Current) 0.15 0.13 +15.38%
Deferred Tax Liabilities (Net) 3.65 1.24 +194.35%
Total Non-Current Liabilities 33.65 106.93 -68.53%
Borrowings (Current) 16.86 16.86 0.00%
Lease Liabilities (Current) 0.47 0.23 +104.35%
Trade Payables (Micro & Small Enterprises) 2.93 3.79 -22.69%
Trade Payables (Others) 91.09 36.93 +146.66%
Other Financial Liabilities (Current) 2.26 1.35 +67.41%
Other Current Liabilities 5.53 0.26 +2026.92%
Provisions (Current) 0.32 0.20 +60.00%
Total Current Liabilities 119.45 59.62 +100.35%
TOTAL EQUITY AND LIABILITIES 463.98 400.86 +15.75%

Cash Flow: Tracking the Money Movement

Consolidated Statement of Cash Flows FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Net Profit Before Tax 0.77 (1.51) N/M
Operating Profit Before Working Capital Changes 7.66 2.78 +175.54%
Cash Generated from Operations (942.21) (115.18) +718.03%
Income Tax Paid / Net (1.01) 2.47 N/M
Net Cash From / (Used in) Operating Activities (A) (10.43) 1.31 N/M
Acquisition of Property, Plant and Equipment and CWIP (Net) / CapEx 34.20 113.85 -69.96%
Sale Proceeds on Property, Plant and Equipment 0.10% 1.98% –
Bank Balances Not Considered as Cash and Cash Equivalents 67.55 23.42 +188.43%
Redemption / (Investment) in Mutual Funds (Net) (26.12) 37.61 N/M
Net Cash From / (Used in) Investing Activities (B) 7.25 (52.77) N/M
Proceeds / (Repayment) from Short-Term Borrowings 0.10% 1.98% –
Proceeds / (Repayment) from Long-Term Borrowings 0.10% 1.98% –
Proceeds from Share Capital / Rights Issue Premium 0.10% 1.98% –
Interest Paid (1.78) (0.18) +888.89%
Net Cash From / (Used in) Financing Activities (C) 1.79 44.65 -95.99%
Net Increase / (Decrease) in Cash and Cash Equivalents (A + B + C) (1.39) (6.80) -79.56%
Opening Balance of Cash and Cash Equivalents 4.92 11.72 -58.02%
Closing Balance of Cash and Cash Equivalents 3.53 4.92 -28.25%

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Name of Director / KMP Designation / Role DIN Category
Mr. Mulesh Manilal Savla Chairman & Director 07474847 Non-Executive Independent Director
Mr. Santosh Shantilal Vora Managing Director 07633923 Executive Managing Director
Mr. Paresh Shashikant Shah Whole-Time Director & Chief Financial Officer 08291953 Executive Director & CFO
Mr. Shantilal Shivji Vora Director 07633852 Non-Executive Director
Mr. Sandeep Gupta Director 09245060 Non-Executive Director
Mrs. Sonal Amit Vira Director 09505883 Non-Executive Independent Director
Mr. Ashok Lakhamshi Chheda Director 10776571 Non-Executive Independent Director
Mr. Akshay Gangurde Company Secretary & Compliance Officer N.A. (ACS: 70561) Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

The shareholding structure of the Company as on March 31, 2026, reflects strong promoter backing coupled with institutional and retail participation across 5,43,12,500 total equity shares.

Category of Equity Shareholder No. of Shares % of Total Shares
Promoter and Promoter Group 4,06,41,487 74.83
Resident Individuals 1,01,22,827 18.64
Body Corporate 16,62,072 3.06
Clearing Members 7,46,383 1.37
Hindu Undivided Family (HUF) 7,99,656 1.47
Body Corp – LLP 1,23,910 0.23
Non-Resident Indians (NRIs) 1,07,366 0.20
Foreign Portfolio Investors (FPI) 1,08,114 0.20
Escrow Demat Account 685 0.00
Total 5,43,12,500 100.00

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

Entity Name Relationship Country % Shareholding Turnover (₹ in Crores) Profit / (Loss) After Tax (₹ in Crores)
Valiant Advanced Sciences Private Limited (VASPL) Wholly Owned Subsidiary India 100.00% 41.65 (8.82)

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Valiant Laboratories derives its economic moat from its established market leadership in the Paracetamol API segment, backed by over 45 years of manufacturing excellence within the Aarti Group. The Company possesses a strong cost-competitive manufacturing platform at Tarapur, supported by ISO 9001:2015 and GMP certifications. Complete backward integration—anchored by localized sourcing of key starting materials like Para-Aminophenol (PAP) from Aarti Group entities and Acetic Anhydride production at subsidiary VASPL—insulates the business from import volatility and secures supply chain continuity.

What Could Go Wrong? Key Challenges & Business Risks

Principal risk factors confronting the business include raw material price volatility, particularly concerning imported key starting materials and global chemical intermediates. The Company faces competitive pricing pressures within the Paracetamol API market driven by sector-wide capacity additions. Additionally, currency fluctuations, evolving environmental and regulatory compliance standards, and fixed cost absorption risks associated with newly commissioned greenfield capacities represent ongoing operational watchpoints.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Strategic priorities focus on accelerating the commercial ramp-up and customer validations of specialty chemical products from the newly operational VASPL greenfield facility at Saykha, Gujarat. Management aims to leverage the deleveraged balance sheet—achieved through the ₹0.81 Crores Rights Issue proceeds applied toward term loan repayment—to pursue WHO-GMP compliance, expand regulated and semi-regulated export footprints, and optimize operational efficiencies across all manufacturing assets.

The Verdict: Strategic Outlook & Conclusion

Valiant Laboratories has successfully navigated industry downcycles by strengthening its balance sheet to a debt-free footing, expanding manufacturing throughput, and executing structural backward integration through VASPL. While initial depreciation and tax charges on newly capitalized assets impacted consolidated bottom-line profitability during FY 2025-26, the standalone business returned firmly to profitable operations. With stabilized operations, enhanced capacities, and dedicated focus on high-purity API production, the Company is well-positioned for sustained progress and value creation.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://valiantlabs.in